AYTU insider filings
AYTU BIOPHARMA, INC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-07-30. Screen AYTU transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for AYTU between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — AYTU BIOPHARMA, INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-30 | 4 | Selhorn Ryan J — Chief Financial Officer | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2026-07-30 | 4 | Disbrow Jarrett — Chief Business Officer | Grant/award (A): 15,000 @ $0 | EDGAR |
| 2026-07-30 | 4 | PYSZCZYMUKA GREG — Chief Commercial Officer | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2026-07-30 | 4 | Disbrow Joshua R. — Chief Executive Officer, Director | Grant/award (A): 30,000 @ $0 | EDGAR |
| 2026-07-30 | 4 | Donofrio John Jr. — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-07-30 | 4 | DOCKERY CARL — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-07-30 | 4 | JAIN ABHINAV — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-07-30 | 4 | LIU VIVIAN H — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2025-10-07 | 4 | PYSZCZYMUKA GREG — Chief Commercial Officer | Grant/award (A): 12,500 @ $0 | EDGAR |
| 2025-10-07 | 4 | Disbrow Jarrett — Chief Business Officer | Grant/award (A): 19,606 @ $0 · Grant/award (A): 12,500 @ $0 | EDGAR |
| 2025-10-07 | 4 | Selhorn Ryan J — Chief Financial Officer | Grant/award (A): 16,243 @ $0 · Grant/award (A): 17,500 @ $0 | EDGAR |
| 2025-10-07 | 4 | Disbrow Joshua R. — Chief Executive Officer, Director | Grant/award (A): 31,446 @ $0 · Grant/award (A): 22,500 @ $0 | EDGAR |
| 2025-10-07 | 4 | JAIN ABHINAV — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2025-10-07 | 4 | DOCKERY CARL — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2025-10-07 | 4 | Donofrio John Jr. — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2025-10-07 | 4 | LIU VIVIAN H — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2025-06-10 | 4 | Disbrow Jarrett — Chief Business Officer | Purchase (P): 16,666 @ $1.50 | EDGAR |
| 2025-06-10 | 4 | Disbrow Joshua R. — Chief Executive Officer | Purchase (P): 66,666 @ $1.50 | EDGAR |
| 2025-06-09 | 4 | Nantahala Capital Management, LLC — 10% owner Harkey Wilmot B. — 10% owner Mack Daniel — 10% owner | Purchase (P): 4,000,000 (derivative) @ $1.50 | EDGAR |
| 2025-03-31 | 4 | PYSZCZYMUKA GREG — Chief Commercial Officer | Option exercise (M): 209 · Option exercise (M): 209 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Disbrow Joshua R. — Chief Executive Officer | Purchase (P): 15,000 @ $1.30 | EDGAR |
| 2025-03-03 | 4 | Selhorn Ryan J — Chief Financial Officer | Option exercise (M): 105 · Option exercise (M): 105 (derivative) @ $0 | EDGAR |
| 2025-01-02 | 4 | PYSZCZYMUKA GREG — Chief Commercial Officer | Option exercise (M): 208 · Option exercise (M): 208 (derivative) @ $0 | EDGAR |
| 2024-11-13 | 4 | Selhorn Ryan J — Chief Financial Officer | Grant/award (A): 14,000 @ $0 | EDGAR |
| 2024-11-08 | 4 | DOCKERY CARL — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2024-11-08 | 4 | Donofrio John Jr. — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2024-11-08 | 4 | JAIN ABHINAV — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2024-11-08 | 4 | Disbrow Joshua R. — Chief Executive Officer, Director | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Disbrow Jarrett — Chief Business Officer | Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | PYSZCZYMUKA GREG — Chief Commercial Officer | Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | LIU VIVIAN H — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2024-11-08 | 4/A | LIU VIVIAN H — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2024-10-02 | 4 | PYSZCZYMUKA GREG — Chief Commercial Officer | Option exercise (M): 209 · Option exercise (M): 209 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | PYSZCZYMUKA GREG — Chief Commercial Officer | Option exercise (M): 208 · Option exercise (M): 208 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Nantahala Capital Management, LLC — 10% owner Harkey Wilmot B. — 10% owner Mack Daniel — 10% owner | Option exercise/expiry (X): 815,217 (derivative) @ $0 · Option exercise/expiry (X): 815,217 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | PYSZCZYMUKA GREG — Chief Commercial Officer | Option exercise (M): 208 · Option exercise (M): 208 (derivative) @ $0 | EDGAR |
| 2024-01-02 | 4 | PYSZCZYMUKA GREG — Chief Commercial Officer | Option exercise (M): 209 · Option exercise (M): 209 (derivative) @ $0 | EDGAR |
| 2023-10-03 | 4 | PYSZCZYMUKA GREG — Chief Commercial Officer | Option exercise (M): 208 · Option exercise (M): 208 (derivative) @ $0 | EDGAR |
| 2023-08-18 | 4 | JAIN ABHINAV — Director | Grant/award (A): 6,500 @ $0 | EDGAR |
| 2023-08-15 | 4 | Disbrow Jarrett — Chief Business Officer | Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | JAIN ABHINAV — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2023-08-15 | 4 | Donofrio John Jr. — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2023-08-15 | 4 | DOCKERY CARL — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2023-08-15 | 4 | Disbrow Joshua R. — Chief Executive Officer, Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | BROOKE CHRISTOPHER — Chief Operating Officer | Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | Oki Mark K — Chief Financial Officer | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | PYSZCZYMUKA GREG — Chief Commercial Officer | Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | LIU VIVIAN H — Director | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2023-07-06 | 4 | PYSZCZYMUKA GREG — Chief Commerical Officer | Option exercise (M): 208 · Option exercise (M): 208 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | PYSZCZYMUKA GREG — Chief Commerical Officer | Option exercise (M): 833 @ $0 · Option exercise (M): 833 (derivative) @ $0 | EDGAR |
Recent 8-K events — AYTU BIOPHARMA, INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-16 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-22 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-25 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AYTU returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs